1. Introduction {#sec1-ijms-18-01045}
===============

Uveitis is defined as an inflammation of the uveal tract, which is composed of the ciliary body, iris and choroid \[[@B1-ijms-18-01045],[@B2-ijms-18-01045]\]. Uveitis is one of the leading causes of permanent and irreversible blindness in young and middle-aged people and accounts for 10--15% of blindness in the Western world \[[@B1-ijms-18-01045],[@B2-ijms-18-01045],[@B3-ijms-18-01045]\]. Uveitis can be caused by infectious and non-infectious factors; the latter include Vogt--Koyanagi--Harada (VKH) syndrome, Behcet's disease (BD), acute anterior uveitis (AAU), birdshot chorioretinopathy (BCR) and some types of cancers. VKH is an autoimmune disease characterized by systemic disorders including poliosis, vitiligo, alopecia, auditory signs and disorders of the central nervous system \[[@B4-ijms-18-01045],[@B5-ijms-18-01045]\]. BD is a chronic multi-systemic inflammatory disease characterized by nongranulomatous uveitis, oral ulcers and skin lesions \[[@B2-ijms-18-01045],[@B6-ijms-18-01045]\]. AAU is the most common non-infectious cause of uveitis and is characterized by self-limiting and recurrent inflammation involving the ciliary and iris body \[[@B7-ijms-18-01045]\]. BCR is a chronic, bilateral, and posterior uveitis that has an almost 100% genetic association with HLA-A29 \[[@B8-ijms-18-01045]\]. Uveitis or uveitis masquerade syndrome could also be induced by some intraocular tumors, such as retinoblastoma and intraocular lymphoma, or their therapeutic approaches \[[@B9-ijms-18-01045],[@B10-ijms-18-01045],[@B11-ijms-18-01045],[@B12-ijms-18-01045],[@B13-ijms-18-01045],[@B14-ijms-18-01045],[@B15-ijms-18-01045]\].

It has been reported that complex genetic mechanisms coupled with an aberrant immune response may be involved in the development of uveitis. In some cases, the pathogenesis of uveitis seemly has a different cause than those described above, such as sarcoidosis \[[@B16-ijms-18-01045]\]. Mutations in different genes and gene families have been discovered in patients. In this study, we focused on the most important causes of uveitis and research for the putative genes involved in these processes. Human leukocyte antigens (*HLA*s) are the major molecules that are important for the development of uveitis, including uveitis associated with VKH (*HLA-DR4*, *DRB1*/*DQA1*), BD (*HLA-B51*), AAU (*HLA-B27*) and BCR (*HLA-A29*). In addition, genome-wide association studies revealed that abnormities of many non-HLA genes such as the interleukin (IL) family and the Signal transducer and activator of transcription 4 (*STAT4*) also participate in the progression of uveitis \[[@B17-ijms-18-01045],[@B18-ijms-18-01045],[@B19-ijms-18-01045]\]. IL23R is associated with both VKH and AAU \[[@B20-ijms-18-01045]\]. Furthermore, copy number variations (CNVs) of Toll-like receptors (*TLR*s), a family of cellular receptors that function in innate immune response, are associated with BD, VKH and AAU. These genes include *TLR*s 1--3, *TLR*s 5--7, and *TLR*s 9--10 \[[@B21-ijms-18-01045]\]. SNPs of TLR4 were also shown to be involved in the development of BD \[[@B22-ijms-18-01045]\]. In addition, it has been demonstrated that there is increased expression of *T-bet* and *IFN-γ*, two genes involved in the Th1 cell pathway, in uveitis patients \[[@B23-ijms-18-01045]\]. The activator of *STAT4* affects *IL-17* production and is a shared risk factor for BD in different cohorts \[[@B17-ijms-18-01045],[@B24-ijms-18-01045]\]. Finally, interleukins (notably *IL-2*, *IL12B*, *IL18* and *IL23R*) are important cytokines that play a pathogenic role in the process of uveitis \[[@B2-ijms-18-01045],[@B17-ijms-18-01045],[@B25-ijms-18-01045]\]. In this study, we mainly focused on the genes that play an important role in the immune system, transcription, or cell adhesion.

Using traditional methods, it is quite difficult to collect these large-scale data and analyze genes synthetically. The microarray is a widely used tool for the identification of novel genes. Microarray analysis has been used to determine a number of genes that are associated with uveitis, including the *IL10* family and several other transcripts \[[@B16-ijms-18-01045],[@B26-ijms-18-01045],[@B27-ijms-18-01045],[@B28-ijms-18-01045],[@B29-ijms-18-01045]\]. In recent years, computational analysis has been applied to identify virulence genes, but many of these genes were identified based on guilt by association (GBA) \[[@B30-ijms-18-01045],[@B31-ijms-18-01045],[@B32-ijms-18-01045]\]. This approach assumes that the candidate genes, which are neighbors of disease genes, are more likely to be new virulence genes. Thus, the GBA-based methods only consider the neighbors of known disease genes to discover novel candidates. Therefore, these methods only examine part of the gene network. Random Walk with Restart (RWR) is another algorithm that identifies disease-related genes \[[@B33-ijms-18-01045],[@B34-ijms-18-01045],[@B35-ijms-18-01045]\]. This algorithm utilizes a set of seed nodes that represent disease genes and performs random walking on the gene network. When the probabilities of all nodes are stable, the probability of a node gene correlating with disease is updated. The genes that correspond to nodes that have high probabilities may be potential novel candidate virulence genes. This method is useful for mining disease genes and to better explore the mechanism of disease. In addition, other studies have adopted the shortest path (SP) algorithm to identify novel disease genes \[[@B36-ijms-18-01045],[@B37-ijms-18-01045],[@B38-ijms-18-01045],[@B39-ijms-18-01045],[@B40-ijms-18-01045],[@B41-ijms-18-01045]\]. By searching the shortest paths that connect any two validated disease genes, genes that are present in these paths could be extracted and considered as novel disease genes. An obvious advantage of the RWR or SP algorithms is that these algorithms utilize the entire gene network and consider more factors, therefore performing a more extensive and reliable analysis.

As discussed above, many genetic factors contribute to the pathogenesis of uveitis. In this study, we utilized computational analyses to build a genetic network based on previously known factors. A computational method was built to identify novel genes related to uveitis. First, a large network was constructed using human protein--protein interactions (PPIs). Next, the RWR algorithm was performed on the network using the validated uveitis-related genes as seed nodes, yielding several possible candidate genes. These candidate genes were filtered based on a set of criteria that were built by *p*-values and their associations with validated uveitis-related genes. To indicate the utility of the method, it was evaluated by five-fold cross-validation, resulting in the average F1-measure of 0.189. Furthermore, the proposed method was compared with a classic GBA-based method \[[@B30-ijms-18-01045],[@B31-ijms-18-01045],[@B32-ijms-18-01045]\] to further prove its effectiveness for identification of uveitis-related genes. Through our method, 56 novel candidate genes were identified and extensively analyzed.

2. Results and Discussion {#sec2-ijms-18-01045}
=========================

2.1. Results of Testing Random Walk with Restart (RWR)-Based Method {#sec2dot1-ijms-18-01045}
-------------------------------------------------------------------

Before the RWR-based method was used to identify novel uveitis-related genes, five-fold cross-validation was adopted to evaluate its utility. For each part, the results yielded by the method on the rest four parts were counted as recall, precision and F1-measure, which are listed in [Table 1](#ijms-18-01045-t001){ref-type="table"}. It can be observed that the average of recall, precision and F1-measure was 0.287, 0.141 and 0.189, respectively. Although these measurements are not very high, the RWR-based method is still acceptable due to the difficulties for identification of novel genes with given functions. Besides, the utility of the RWR-based method would be further proved by comparing it with other methods, which is described in [Section 2.5](#sec2dot5-ijms-18-01045){ref-type="sec"}.

2.2. RWR Genes {#sec2dot2-ijms-18-01045}
--------------

Based on the uveitis-related genes, the RWR algorithm yielded a probability for each gene in the PPI network, which indicated the likelihood of the gene being important for uveitis. Then, genes were selected that had probabilities larger than 10^−5^. From our analysis, we obtained 3641 RWR genes, which are provided with their RWR probabilities in [Supplementary Table S1](#app1-ijms-18-01045){ref-type="app"}.

2.3. Candidate Genes {#sec2dot3-ijms-18-01045}
--------------------

According to the RWR-based method detailed in [Section 3.3](#sec3dot3-ijms-18-01045){ref-type="sec"}, RWR genes were filtered using a permutation test. For each RWR gene, a *p*-value was assigned to indicate whether the RWR gene is specific for uveitis. The *p*-value for each of the 3641 RWR genes is also provided in [Supplementary Table S1](#app1-ijms-18-01045){ref-type="app"}. We found 1231 candidate genes that had a *p*-value \< 0.05 (see the first 1231 genes in [Supplementary Table S1](#app1-ijms-18-01045){ref-type="app"}).

The 1231 candidate genes were then further analyzed using the criteria outlined in [Section 3.3](#sec3dot3-ijms-18-01045){ref-type="sec"}. For each candidate gene, MIS (cf. Equation (3)) and MFS (cf. Equation (5)) were calculated, and the values for each gene are available in [Supplementary Table S1](#app1-ijms-18-01045){ref-type="app"}. The threshold for MIS was set at 900, while 0.8 was used as the threshold for MFS. Finally, we obtained 56 Ensembl IDs (listed in [Table 2](#ijms-18-01045-t002){ref-type="table"}) corresponding to core candidate genes. These genes were deemed to be highly related to uveitis and could be considered novel candidate genes. As intuitionistic evidence, a sub-network was plotted in [Figure 1](#ijms-18-01045-f001){ref-type="fig"}, which contains the putative and validated genes. Each putative gene had strong associations with validated genes, implying that they had functions similar to those of the validated genes and may be novel uveitis-related genes with high probabilities.

2.4. Analysis of Novel Genes {#sec2dot4-ijms-18-01045}
----------------------------

In this study, the RWR-based method yielded fifty-six genes that were deemed to have a significant correlation with uveitis. Detailed information for these genes is provided in [Table 2](#ijms-18-01045-t002){ref-type="table"}.

### 2.4.1. Immune System Regulation Genes {#sec2dot4dot1-ijms-18-01045}

*CCL4* (C-C motif chemokine ligand 4) belongs to the cytokine family and is involved in immunoregulation and inflammation. It has been reported that *CCL4* is associated with BD immunopathogenesis \[[@B42-ijms-18-01045]\]. In the majority of VKH cases, the expression of another family member *CCL17* was lower in cerebrospinal fluid than in serum, which indicated its potential function in VKH \[[@B43-ijms-18-01045]\]. *CCL17* also could be inhibited by overexpression of *SOCS1* in the retina to regulate the recruitment of inflammatory cells \[[@B44-ijms-18-01045]\]. The cytokine *CCL20* was considered to be a specific biomarker of *HLA-B27*-associated uveitis \[[@B45-ijms-18-01045]\]. Our study revealed that *CCL4*, *CCL17* and *CCL20* likely play essential roles in uveitis.

*CD40* ligand (also known as *CD154*) is a type II transmembrane glycoprotein that has structural homology to the proteins of the *TNF* (tumor necrosis factor) family \[[@B46-ijms-18-01045],[@B47-ijms-18-01045],[@B48-ijms-18-01045],[@B49-ijms-18-01045]\]. The interaction between the *CD40* and *CD40 ligand* is important for both cellular and humoral immune responses \[[@B50-ijms-18-01045]\]. The *CD40* and *CD40 ligand* interaction provides signals in T-cell priming and effecter functions \[[@B46-ijms-18-01045],[@B48-ijms-18-01045],[@B49-ijms-18-01045],[@B51-ijms-18-01045],[@B52-ijms-18-01045],[@B53-ijms-18-01045]\], whereas monocyte and B-cell apoptosis could be inhibited by their interaction \[[@B54-ijms-18-01045]\]. It has been demonstrated that the *CD40* ligand is associated with the immune-pathogenesis of several autoimmune diseases including AU (anterior uveitis) \[[@B54-ijms-18-01045],[@B55-ijms-18-01045]\]. The *CD40* ligand is significantly expressed on T-cells in the peripheral blood of patients with AU \[[@B56-ijms-18-01045]\]. The results of the RWR-based method revealed a MIS of 999 had a *p*-value \< 0.001. Expression of *CD80* on dendritic cells (DCs) could be induced by activation of *NOD1* and *NOD2* and is involved in the pathogenesis of VKH syndrome \[[@B57-ijms-18-01045]\]. In another report, it was found that BBR downregulated the expression of costimulatory molecules *CD40*, *CD80* and *CD86* on *DC*s \[[@B58-ijms-18-01045]\]. The MIS and *p*-value of *CD80* were 999 and \<0.001, respectively. We speculate that these molecules play key roles in uveitis, but their mechanism in uveitis must still be clarified.

*CSF2* (colony stimulating factor 2) is a cytokine that functions as a hematological cell growth factor by stimulating stem cells to produce granulocytes and monocytes \[[@B59-ijms-18-01045]\]. Three signaling pathways can be activated by *CSF2*: the JAK2/STAT pathway, the MAP pathway and the PI3K pathway \[[@B60-ijms-18-01045],[@B61-ijms-18-01045],[@B62-ijms-18-01045],[@B63-ijms-18-01045],[@B64-ijms-18-01045]\]. *CSF2* is a valuable prognostic indicator and a therapeutic target in tumors \[[@B59-ijms-18-01045]\]. *CSF2* expression in uveitis is reported as rare. However, in this study, the MIS of *CSF2* was 992 with a *p*-value \< 0.001. We speculate that *CSF2* might be a key factor in the pathogenesis of uveitis.

Interleukins and their receptors are inflammatory cytokines that play an important role in immune system response. Many interleukins and their receptors are involved in uveitis, as discussed above. Our data showed that *IL13*, *IL15*, *IL1A*, *IL1B*, *IL1RN*, *IL4*, *IL5*, *IL9*, *IL23A* and *IL2RA* had MISs larger than 900 with *p*-values \<0.05. It has been observed that the expression of *IL1A* is decreased in patients with clinically active BD, while the expression of *IL1B* is increased in patients with active, inactive or ocular BD \[[@B65-ijms-18-01045]\]. IL1B has been associated with ocular Behcet's disease \[[@B66-ijms-18-01045]\]. *IL-13* is a strong immunomodulatory cytokine which is a promising mode of treatment for uveitis \[[@B67-ijms-18-01045],[@B68-ijms-18-01045],[@B69-ijms-18-01045],[@B70-ijms-18-01045]\]. *IL-15* and its receptor system is involved in the inflammatory process and pathogenesis of BD and the IL-15/Fc fusion protein has been shown to inhibit IRBP1-20 specific CD80+ T cell to decrease the severity of EAU \[[@B71-ijms-18-01045],[@B72-ijms-18-01045]\]. An aberrantly high CNV of *IL23A* is a common risk factor for VKH and BD \[[@B73-ijms-18-01045]\]. In mice, *IL-1RN* suppresses immune-mediated ocular inflammation and is considered a potential biomarker in the management of patients with uveitis \[[@B74-ijms-18-01045]\]. Interleukin 2 receptor α (*IL2RA*) is a risk locus in various autoimmune diseases and a variant of this gene, *rs2104286*, was demonstrated to be strongly associated with intermediated uveitis \[[@B75-ijms-18-01045]\]. An antibody against *IL2RA*, daclizumab is used to reduce intermediated uveitis \[[@B76-ijms-18-01045]\]. However, *rs2104286* was not related to endogenous non-anterior uveitis \[[@B77-ijms-18-01045]\]. EAU (experimental autoimmune uveoretinitis) disease severity was reduced in mice in which *IL-1B* expression was reduced in the retina through deletion of S100B, a Ca^2+^ binding protein \[[@B78-ijms-18-01045]\]. In a Lewis rat model of EAU, *IL-2* and *IL-4* were produced in destructive foci in the retina and uveal tract. *IL-2* is thought to act as a cytotoxic effector, while *IL-4* is associated with a helper cell function \[[@B79-ijms-18-01045]\]. In patients with BD, *IL-2* is more highly expressed, while *IL-4* is more lowly expressed \[[@B80-ijms-18-01045]\]. Genetic findings suggest that more work should be done to evaluate both the molecular target and the inhibitor for personalized therapy.

*TLR2*, *TLR3*, *TLR7* and *TLR9* belong to the Toll-like receptor (*TLR*) family, which are key factors in pathogen recognition and activation of innate immunity. *TLR*s are thought to be associated with infection and auto-inflammatory or autoimmune diseases, including uveitis \[[@B81-ijms-18-01045],[@B82-ijms-18-01045]\]. Several autoimmune diseases, including BD, are associated with certain *TLR* gene polymorphisms \[[@B83-ijms-18-01045],[@B84-ijms-18-01045]\]. A significant association has been found between polymorphism of TLR2 and ocular BD patients \[[@B85-ijms-18-01045]\]. The expression of *TLR4* was significantly up-regulated in monocyte-derived macrophages from VKH patients \[[@B86-ijms-18-01045]\]. The chitosan-mediated TLR3-siRNA transfection had a potential therapeutic effect on remitting uveitis \[[@B87-ijms-18-01045]\]. In a Chinese Han population, a high copy number of TLR7 conferred risk for BD patients \[[@B88-ijms-18-01045]\]. In the Japanese population, the homozygous genotypes and homozygous deplotype configuration of TLR9 SNPs was associated with the susceptibility to BD \[[@B89-ijms-18-01045]\]. It has been reported that glucocorticoid could improve uveitis by downregulating *TLR7* and *TLR9* in peripheral blood of patients with uveitis \[[@B90-ijms-18-01045]\]. In our analysis, *TLR2*, *TLR3*, *TLR7* and *TLR9* have MIS scores of 968, 966, 926 and 958, respectively. We argue that *TLR2*, *TLR3*, *TLR7* and *TLR8* play essential roles in uveitis and thus require more attention.

### 2.4.2. Transcription Associated Genes {#sec2dot4dot2-ijms-18-01045}

*Jun* (also known as jun proto-oncogene) is a critical subunit of the transcription factor AP1, which is an important modulator of diverse biological processes such as cell proliferation, apoptosis and malignant transformation \[[@B91-ijms-18-01045]\]. Jun is activated through phosphorylation at Ser 63 and Ser 73 by *JNK* \[[@B92-ijms-18-01045],[@B93-ijms-18-01045]\]. A high level of *Jun* has been observed in various types of cancer including non-small cell lung cancer, oral squamous cell carcinoma, breast cancer and colorectal cancer \[[@B94-ijms-18-01045],[@B95-ijms-18-01045],[@B96-ijms-18-01045],[@B97-ijms-18-01045],[@B98-ijms-18-01045]\]. Overexpression of *Jun* has led to aberrant tumor growth and progression and inhibited cell apoptosis \[[@B94-ijms-18-01045]\]. The underlying mechanism of *Jun* as it relates to uveitis is still unclear. In a gene screen assay, it was found that expression of *Jun* showed a significantly higher index in experimental lens-induced uveitis rabbits \[[@B99-ijms-18-01045]\]. In our analysis, *Jun* showed a significant index *p*-value and an MIS of 999; therefore, we propose that Jun may be an essential factor in uveitis.

*STAT1* and *STAT6* encode transcription factors that belong to the *STAT* family, where phosphorylation is activated by receptor associated kinases. Atopic dermatitis associated uveitis may be driven by TH2-mediated inflammation \[[@B100-ijms-18-01045]\]. *IL-4* is a TH2 cytokine, and binding with its receptor can activate *STAT6* via the (Jak) Janus kinase/STAT signaling pathway to promote many immunomodulatory genes \[[@B101-ijms-18-01045]\]. Furthermore, the Stat6 VT (STAT6 V547A/T548A) mouse model of atopic dermatitis exhibited uveitis symptoms \[[@B100-ijms-18-01045]\]. In the STAT family, TH17 cells can be induced by *IL-2* and suppressed by *IL-27*/*STAT1* to contribute to uveitis \[[@B102-ijms-18-01045]\]. In this study, *STAT1* and *STAT6* both had significant *p*-values and MIS of 999, and therefore we hypothesize that *STAT1/6* function has a putative role in uveitis.

### 2.4.3. Cell Adhesion and Signal Transduction Related Genes {#sec2dot4dot3-ijms-18-01045}

Matrix metalloproteinase (*MMP*) are key factors for the degradation of extracellular matrix components and modification of cytokines, protease inhibitors, and cell surface signaling systems \[[@B103-ijms-18-01045],[@B104-ijms-18-01045],[@B105-ijms-18-01045],[@B106-ijms-18-01045]\]. Polymorphisms on the *MMP-9* promoter can affect the development of visceral involvement in Korean people with BD \[[@B107-ijms-18-01045]\]. In our RWR analysis, *MMP9* had an MIS of 971 and a *p*-value \< 0.001, which suggests that *MMP-9* may be a novel susceptibility gene for uveitis.

*VCAM1* (vascular cell adhesion molecule 1) belongs to the Ig superfamily and is a cell surface sialoglycoprotein expressed by cytokine-activated endothelium. This protein is mediated by leukocyte-endothelial cell adhesion and signal transduction \[[@B108-ijms-18-01045],[@B109-ijms-18-01045]\]. *VCAM1* can be regulated by inflammatory cytokines such as *IL1B* \[[@B108-ijms-18-01045]\]. Uveitis is closely associated with the immune system and immune-related proteins including the interleukin family. In our study, the MIS of *VCAM1* was 968 and the *p*-value was less than 0.05, which makes *VCAM1* a candidate gene for uveitis.

We detected 56 novel uveitis-related genes using the RWR-based method. These genes can be clustered into three categories, shown in [Figure 2](#ijms-18-01045-f002){ref-type="fig"}. Among these 56 potential genes, eight (8/56, 14.3%) genes, *IL13*, *IL1RN*, *JAK1*, *MYD88*, *NOD1*, *PTGS2*, *TGFB1* and *TLR3*, were considered as uveitis genes by experimental evidence \[[@B110-ijms-18-01045],[@B111-ijms-18-01045],[@B112-ijms-18-01045],[@B113-ijms-18-01045],[@B114-ijms-18-01045],[@B115-ijms-18-01045],[@B116-ijms-18-01045],[@B117-ijms-18-01045]\], and 29 (29/56, 51.8%) genes (*CASP8*, *CCL17*, *CCL20*, *CCL4*, *CD19*, *CD40 LG*, *CD80*, *CXCL1*, *CXCL11*, *CXCL13*, *CXCL16*, *CXCL5*, *CXCL9*, *CXCR2*, *IL15*, *IL1A*, *IL1B*, *IL23A*, *IL2RA*, *IL4*, *JUN*, *MMP9*, *STAT1*, *STAT6*, *TLR2*, *TLR7*, *TLR9*, *TNFRSF1A* and *VCAM1*) had a correlation with uveitis. However, the pathogenesis is not clear. In our results, we found that these genes have a significant relationship with uveitis genes and therefore need more validation. There are few reports of the rest of the genes (19/56, 33.9%) (*CCR8*, *CD276*, *CD8A*, *CSF2*, *CSF3*, *CXCR1*, *CXCR5*, *CXCR6*, *GAPDH*, *GZMB*, *HLA-DB5*, *IL5*, *IL9*, *KITLG*, *MAPK8*, *PTPRC*, *SELE*, *TGFB3* and *TGFBI*) which participate in the process of uveitis. We considered that they might be novel uveitis genes and merit attention. We argue that some of these may be critical putative virulence genes for uveitis and could be interesting agents for the treatment of human uveitis.

2.5. Comparison of Other Methods {#sec2dot5-ijms-18-01045}
--------------------------------

The results listed in [Section 2.1](#sec2dot1-ijms-18-01045){ref-type="sec"}, [Section 2.2](#sec2dot2-ijms-18-01045){ref-type="sec"}, [Section 2.3](#sec2dot3-ijms-18-01045){ref-type="sec"} and [Section 2.4](#sec2dot4-ijms-18-01045){ref-type="sec"} can partly prove the effectiveness of the RWR-based method. In this section, we compared our method with a classic GBA-based method \[[@B30-ijms-18-01045],[@B31-ijms-18-01045],[@B32-ijms-18-01045]\], i.e., a method like the nearest neighbor algorithm (NNA). This method identified novel genes from neighbors of the uveitis-related genes in a network. For convenience, we directly used the PPI network that was adopted in the RWR-based method. In addition, we called a neighbor of a node is a nearer neighbor if the edge between them was assigned a higher weight due to the definition of the interaction score reported in STRING. The GBA-based method selected the *k* nearest neighbors of each uveitis-related genes and collected them together as the predicted genes of the method, where *k* is a predefined parameter.

The five-fold cross-validation method was also adopted to test the GBA-based method, which used the same partition in testing the RWR-based method. Because we do not know the best value of *k*, we tried the following values: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100. The testing results are provided in [Supplementary Table S2](#app1-ijms-18-01045){ref-type="app"}. The best performance of the GBA-based method with different parameter *k* on each part is shown in [Table 3](#ijms-18-01045-t003){ref-type="table"}. Compared with the testing results of RWR-based method, also listed in [Table 3](#ijms-18-01045-t003){ref-type="table"} for convenience, we can see that GBA-based method provides higher recalls sometimes, however, it always provides lower precisions, indicating the GBA-based method can yield more false positive genes. If only considering the F1-measure, we can conclude that F1-measures of the RWR-based method are always higher than those of the GBA-based method. It is indicated that the RWR-based method is superior to GBA-based method for identification of uveitis-related genes.

3. Materials and Methods {#sec3-ijms-18-01045}
========================

3.1. Materials {#sec3dot1-ijms-18-01045}
--------------

Uveitis-related genes were collected from literatures indexed by PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>). The keywords "uveitis" and "genes" were used to search the literature in PubMed, which resulted in the collection of 744 papers. Among them, 98 review papers that generally summarized uveitis-related genes were manually reviewed. From those 98 papers, 121 genes were chosen from 96 reviews reporting the functional genes that may be important for uveitis or for specific uveitis symptoms. These genes are provided in [Supplementary Table S3](#app1-ijms-18-01045){ref-type="app"}. In total, 146 Ensembl IDs for these genes were also determined and are provided in [Supplementary Table S3](#app1-ijms-18-01045){ref-type="app"}.

3.2. Protein-protein Interaction (PPI) Network {#sec3dot2-ijms-18-01045}
----------------------------------------------

PPIs are useful for the investigation of genetic disorders because they play an essential role in intracellular and intercellular biochemical processes. Many computational methods have been developed using this information, such as the prediction engines for the identification of protein functions \[[@B118-ijms-18-01045],[@B119-ijms-18-01045],[@B120-ijms-18-01045]\] and methods for identification of novel disease genes \[[@B36-ijms-18-01045],[@B37-ijms-18-01045],[@B38-ijms-18-01045]\]. Several methods were built based on the hypothesis that two proteins in a PPI are more likely to share similar functions. Thus, we can infer novel genes related to uveitis using PPI information and the uveitis-related genes mentioned in [Section 3.1](#sec3dot1-ijms-18-01045){ref-type="sec"}.

In this study, we used the PPI information retrieved from STRING (Search Tool for the Retrieval of Interacting Genes/Proteins, Version 9.1, <http://string-db.org/>) \[[@B121-ijms-18-01045]\] to construct the PPI network that the RWR algorithm can be applied. To access the PPI information in STRING, we downloaded the file "protein.links.v9.1 txt.gz". Because "9606" is the organism code for the human interactome in STRING, lines in this file that started with "9606" were extracted, obtaining 2,425,314 human PPIs involving 20,770 proteins. According to STRING, these PPIs were derived from the following four sources: (1) genomic context; (2) high-throughput experiments; (3) (conserved) co-expression; and (4) previous knowledge. Thus, the information in STRING contained both the direct (physical) and the indirect (functional) association between proteins, therefore STRING could widely measure the associations between proteins. Each PPI contained two Ensembl IDs and one score that ranged between 150 and 999, which indicated the strength of the interaction. An interaction with a high score meant this interaction has a high probability of occurring. For each interaction containing proteins *p~a~* and *p~b~*, the score was denoted by *S*(*p~a~*,*p~b~*). The PPI network defined the 20,770 proteins as the nodes, and two nodes were adjacent if and only if their corresponding proteins can form a PPI. Additionally, each edge in the network represented a PPI; thus, we assigned a weight to each edge, which was defined as the score of its corresponding PPI. From our analysis, a PPI network containing 20,770 nodes and 2,425,314 edges was obtained.

3.3. RWR-Based Method {#sec3dot3-ijms-18-01045}
---------------------

The RWR algorithm was executed on the PPI network using validated genes as seed nodes to search possible genes. Then, a permutation test was executed to exclude false discoveries found by RWR. The remaining candidate genes with strong associations to validated genes were selected for further analysis. The pseudo-codes of the RWR-based method are listed in [Table 4](#ijms-18-01045-t004){ref-type="table"}.

### 3.3.1. Searching Possible Genes Using the RWR Algorithm {#sec3dot3dot1-ijms-18-01045}

RWR is a type of ranking algorithm \[[@B33-ijms-18-01045]\]. Based on a seed node or a set of seed nodes, it simulates a walker that starts from the nodes and randomly walks in a network. Here, 146 Ensembl IDs listed in [Supplementary Table S3](#app1-ijms-18-01045){ref-type="app"} were deemed as seed nodes. Starting from these nodes, we attempted to discover novel nodes (genes) related to uveitis. In the beginning of the RWR algorithm, a 20,770-D vector *P*~0~ was constructed, in which each composition represented the probability that a node in the network was a uveitis-related gene. Because the 146 Ensembl IDs represented validated uveitis-related genes, their compositions in *P*~0~ were set to 1/146, while others were set to zero. Then, the RWR algorithm repeatedly updated this probability vector until it became stable. We designated *P~i~* to represent the probability vector after the *i*-th step was executed. The probability vector was updated according to the following equation: $$P_{i + 1} = (1 - r)A^{T}P_{i} + rP_{0}$$ where *A* represented the column-wise normalized adjacency matrix of the PPI network and *r* was set to 0.8. When $\left\| {P_{t + 1} - P_{t}} \right\|_{L_{1}} < 10^{- 6}$, the update procedure was stopped, and *P~t~*~+1~ was the output of the RWR algorithm.

According to the probability vector yielded by the RWR algorithm, some nodes received high probabilities. It was apparent that their corresponding genes are more likely to be uveitis-related genes. To avoid missing possible uveitis-related genes, we set a probability threshold of 10^−5^. The corresponding genes of these nodes were designated as RWR genes.

In this study, we used the RWR program on the heterogeneous network that was implemented in Matlab and proposed by Li and Patra \[[@B122-ijms-18-01045]\]. The code can be downloaded at <http://www3.ntu.edu.sg/home/aspatra/research/Yongjin_BI2010.zip>. By setting the special values of some parameters, this program could be used to execute the RWR algorithm on a single network.

### 3.3.2. Excluding False Discoveries Using the Permutation Test {#sec3dot3dot2-ijms-18-01045}

Based on the validated uveitis-related genes and RWR algorithm, new RWR genes were accessed. However, this result was influenced by the structure of the constructed PPI network, i.e., some RWR genes were selected due to the structure of the network and they were not necessarily unique to uveitis. Furthermore, if we randomly selected some nodes in the network as seed nodes of the RWR algorithm, these genes were still selected for and were therefore deemed as likely to be false positive. To control for these genes, a permutation test was executed. We randomly constructed 1000 Ensembl ID sets, denoted by $E_{1},E_{2},\ldots,E_{1000}$, consisting of 146 Ensembl IDs. For each set, the Ensembl IDs were deemed seed nodes of the RWR algorithm. Each RWR gene was given a probability. Thus, there were 1000 probabilities for 1000 sets and one probability for 146 Ensembl IDs of the uveitis-related genes for each RWR gene. Then, a measurement, called the *p*-value, was counted for each RWR gene *g*, which was defined as: $$p - {value}(g) = \frac{\Theta}{1000}$$ where $\Theta$ represented the number of randomly constructed sets where the probability assigned to *g* was larger than that for the 146 Ensembl IDs of uveitis-related genes. Clearly, an RWR gene with a high *p*-value indicated that the gene was not specific for uveitis and should be discarded. RWR genes with *p*-values less than 0.05 were selected for further analysis as potential candidate genes for uveitis.

### 3.3.3. Selection of Core Genes by Associations with Validated Genes {#sec3dot3dot3-ijms-18-01045}

We hypothesized that, of the candidate genes, some may have a strong correlation with uveitis. To further select core candidate genes, two criteria were designed. Candidate genes satisfying both criteria were selected for additional analysis. Candidate genes that had the strongest associations with uveitis-related genes were more likely to be novel uveitis-related genes. Thus, for each candidate gene *g*, we calculated the maximum interaction score (MIS) as follows: $$MIS(g) = \max\left\{ S(g,g^{\prime}):g^{\prime}{is}\ a\ {uveitis} - {related}\ {gene} \right\}$$

A high MIS suggested that the candidate gene was closely related to at least one uveitis-related gene, indicating that it was a novel uveitis-related gene with a high probability. According to STRING, a score of 900 was the cut-off for the highest confidence level. Therefore, candidate genes with MISs larger than 900 were selected.

Validated uveitis-related genes have strong associations with specific gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Therefore, candidate genes that had similar associations with uveitis GO terms and KEGG pathways were more likely to be novel uveitis-related genes. We performed GO term (KEGG pathway) \[[@B123-ijms-18-01045],[@B124-ijms-18-01045],[@B125-ijms-18-01045],[@B126-ijms-18-01045]\] enrichment analysis for candidate genes and uveitis-related genes. The representation of a gene *g* on all GO terms and KEGG pathways was encoded into a vector ES (g) using this theory. This vector can be obtained by an in-house program using the R function phyper. The R code used was "score \<− −log10 (phyper (numWdrawn− 1, numW, numB, numDrawn, lower.tail = FALSE))," where numW, numB, and numDrawn are the number of genes annotated to the GO term or KEGG pathway, the number of genes not annotated to the GO term or KEGG pathway, and the number of neighbors of gene g and numWdrawn is the number of neighbors of gene g that are also annotated to the GO term or KEGG pathway. The relativity of the two genes g and $g^{\prime}$ on GO terms and KEGG pathways was measured by $$\Gamma(g,g^{\prime}) = \frac{ES(g) \cdot ES(g^{\prime})}{\left\| {ES(g)} \right\| \cdot \left\| {ES(g^{\prime})} \right\|}$$

A high outcome of Equation (4) indicated that *g* and $g^{\prime}$ have a similar relationship in terms of GO terms and KEGG pathways. For any candidate gene *g*, we calculated the maximum function score (MFS) using the following equation: $$MFS(g) = \max\left\{ \Gamma(g,g^{\prime}):g^{\prime}{is}\ a\ {uveitis} - {related}\ {gene} \right\}$$

Candidate genes with high MFSs were selected. In this equation, we set 0.8 as the threshold of MFS to select essential candidate genes.

3.4. Methods for Testing RWR-Based Method {#sec3dot4-ijms-18-01045}
-----------------------------------------

In this study, we designed the RWR-based method to identify novel uveitis-related genes. However, it is necessary to test its effectiveness in advance. Here, the five-fold cross-validation \[[@B127-ijms-18-01045]\] was employed. In detail, 146 Ensembl IDs of uveitis-related genes were randomly and equally divided into five parts. Then, Ensembl IDs in each part were singled out in turn and other Ensembl IDs in the rest four parts were used as the seed nodes in the RWR-based method. For each part, the results yielded by a good identification method on the rest four parts should satisfy the following conditions: (I) the results can recover a high proportion of the Ensembl IDs in the part; and (II) the results cannot contain several Ensembl IDs that are not in the part. Thus, recall and precision were employed to evaluate the results yielded by the RWR-based method, which can be calculated by $$\left\{ \begin{array}{l}
{{recall} = \frac{TP}{TP + FN}} \\
{{precision} = \frac{TP}{TP + FP}} \\
\end{array} \right.$$ where *TP* represented the number of Ensembl IDs in the part that can be recovered by the method, *FN* represented the number of Ensembl IDs in the part that cannot be recovered by the method and *FP* represented the number of Ensembl IDs that were yielded by the method and not in the part. In addition, to evaluate the predicted results on the whole, the F1-measure was also adopted, which can be computed by $$F1 - {measure} = \frac{2 \times {recall} \times {precision}}{{recall} + {precision}}$$

It is clear that a high F1-measure means the good performance of the method.

4. Conclusions {#sec4-ijms-18-01045}
==============

This study presented a computational method to determine novel uveitis-related genes. Using the RWR algorithm and certain screening criteria, 56 putative genes were accessed. Extensive analysis of the obtained genes confirmed that several genes are associated with the pathogenesis of uveitis. We hope that the identified novel genes may be used as material to study uveitis and that the proposed method can be extended to other diseases.
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![The sub-network of the large network containing Ensembl Identifications (IDs) of validated and putative uveitis-related genes. Blue nodes represent Ensembl IDs of validated uveitis-related genes. Green nodes represent Ensembl IDs of putative uveitis-related genes.](ijms-18-01045-g001){#ijms-18-01045-f001}

![Clustering results of the 56 novel genes according to their evidences for being novel uveitis-related genes. Among 56 novel genes, eight have experiment evidence, 29 have significant relationship with uveitis but without experiment evidence, while no evidence can be found for the rest genes.](ijms-18-01045-g002){#ijms-18-01045-f002}
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###### 

The performance of the Random Walk with Restrart (RWR)-based method yielded by five-fold cross-validation.

  Index of Part   Recall   Precision   F1-Measure
  --------------- -------- ----------- ------------
  1               0.172    0.089       0.118
  2               0.172    0.088       0.116
  3               0.379    0.177       0.242
  4               0.310    0.141       0.194
  5               0.400    0.211       0.276
  Mean            0.287    0.141       0.189
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###### 

Novel genes inferred by Random Walk with Restrart (RWR)-based method.

  Ensembl ID            Gene Symbol   Description                                              Probability     *p*-Value   MIS   MFS
  --------------------- ------------- -------------------------------------------------------- --------------- ----------- ----- -------
  ENSP00000351671 ^b^   *CCL20*       C-C motif chemokine ligand 20                            1.65 × 10^−4^   \<0.001     999   0.841
  ENSP00000250151 ^b^   *CCL4*        C-C motif chemokine ligand 4                             1.64 × 10^−4^   \<0.001     994   0.820
  ENSP00000326432 ^c^   *CCR8*        C-C motif chemokine receptor 8                           8.90 × 10^−5^   \<0.001     951   0.816
  ENSP00000313419 ^b^   *CD19*        CD19 molecule                                            2.15 × 10^−4^   \<0.001     947   0.837
  ENSP00000320084 ^c^   *CD276*       CD276 molecule                                           1.91 × 10^−4^   \<0.001     955   0.823
  ENSP00000359663 ^b^   *CD40LG*      CD40 ligand                                              1.97 × 10^−4^   \<0.001     999   0.839
  ENSP00000264246 ^b^   *CD80*        CD80 molecule                                            2.18 × 10^−4^   \<0.001     999   0.820
  ENSP00000283635 ^c^   *CD8A*        CD8a molecule                                            1.91 × 10^−4^   \<0.001     990   0.815
  ENSP00000296871 ^c^   *CSF2*        Colony stimulating factor 2                              2.71 × 10^−4^   \<0.001     992   0.875
  ENSP00000225474 ^c^   *CSF3*        Colony stimulating factor 3                              1.55 × 10^−4^   \<0.001     916   0.829
  ENSP00000379110 ^b^   *CXCL1*       C-X-C motif chemokine ligand 1                           1.69 × 10^−4^   \<0.001     973   0.827
  ENSP00000306884 ^b^   *CXCL11*      C-X-C motif chemokine ligand 11                          1.28 × 10^−4^   \<0.001     999   0.818
  ENSP00000286758 ^b^   *CXCL13*      C-X-C motif chemokine ligand 13                          1.49 × 10^−4^   \<0.001     986   0.806
  ENSP00000293778 ^b^   *CXCL16*      C-X-C motif chemokine ligand 16                          1.02 × 10^−4^   \<0.001     952   0.800
  ENSP00000296027 ^b^   *CXCL5*       C-X-C motif chemokine ligand 5                           1.11 × 10^−4^   \<0.001     958   0.811
  ENSP00000354901 ^b^   *CXCL9*       C-X-C motif chemokine ligand 9                           2.13 × 10^−4^   \<0.001     999   0.883
  ENSP00000295683 ^c^   *CXCR1*       C-X-C motif chemokine receptor 1                         8.67 × 10^−5^   \<0.001     999   0.833
  ENSP00000319635 ^b^   *CXCR2*       C-X-C motif chemokine receptor 2                         1.02 × 10^−4^   \<0.001     999   0.851
  ENSP00000229239 ^c^   *GAPDH*       Glyceraldehyde-3-phosphate dehydrogenase                 2.12 × 10^−4^   \<0.001     922   0.824
  ENSP00000216341 ^c^   *GZMB*        Granzyme B                                               2.46 × 10^−4^   \<0.001     991   0.829
  ENSP00000364114 ^c^   *HLA-DRB5*    Major histocompatibility complex, class II, DR β 5       2.27 × 10^−4^   \<0.001     948   0.822
  ENSP00000304915 ^a^   *IL13*        Interleukin 13                                           1.31 × 10^−4^   \<0.001     999   0.813
  ENSP00000296545 ^b^   *IL15*        Interleukin 15                                           1.85 × 10^−4^   \<0.001     946   0.806
  ENSP00000263339 ^b^   *IL1A*        Interleukin 1 α                                          1.82 × 10^−4^   \<0.001     996   0.820
  ENSP00000263341 ^b^   *IL1B*        Interleukin 1 β                                          3.58 × 10^−4^   \<0.001     999   0.873
  ENSP00000259206 ^a^   *IL1RN*       Interleukin 1 receptor antagonist                        1.68 × 10^−4^   \<0.001     999   0.836
  ENSP00000228534 ^b^   *IL23A*       Interleukin 23 subunit Α                                 2.87 × 10^−4^   \<0.001     998   0.844
  ENSP00000369293 ^b^   *IL2RA*       Interleukin 2 receptor subunit Α                         2.46 × 10^−4^   \<0.001     999   0.866
  ENSP00000274520 ^c^   *IL9*         Interleukin 9                                            1.27 × 10^−4^   \<0.001     965   0.806
  ENSP00000360266 ^b^   *JUN*         Jun proto-oncogene, AP-1 transcription factor subunit    3.22 × 10^−4^   \<0.001     999   0.831
  ENSP00000361405 ^b^   *MMP9*        Matrix metallopeptidase 9                                1.70 × 10^−4^   \<0.001     971   0.833
  ENSP00000379625 ^a^   *MYD88*       Myeloid differentiation primary response 88              1.82 × 10^−4^   \<0.001     999   0.882
  ENSP00000356346 ^c^   *PTPRC*       Protein tyrosine phosphatase, receptor type C            2.18 × 10^−4^   \<0.001     994   0.826
  ENSP00000331736 ^c^   *SELE*        Selectin E                                               1.46 × 10^−4^   \<0.001     978   0.830
  ENSP00000354394 ^b^   *STAT1*       Signal transducer and activator of transcription 1       2.63 × 10^−4^   \<0.001     999   0.852
  ENSP00000300134 ^b^   *STAT6*       Signal transducer and activator of transcription 6       1.77 × 10^−4^   \<0.001     999   0.804
  ENSP00000221930 ^a^   *TGFB1*       Transforming growth factor β 1                           2.90 × 10^−4^   \<0.001     997   0.832
  ENSP00000416330 ^c^   *TGFBI*       Transforming growth factor β induced                     1.91 × 10^−4^   \<0.001     917   0.813
  ENSP00000260010 ^b^   *TLR2*        Toll like receptor 2                                     2.25 × 10^−4^   \<0.001     968   0.888
  ENSP00000370034 ^b^   *TLR7*        Toll like receptor 7                                     1.26 × 10^−4^   \<0.001     926   0.819
  ENSP00000353874 ^b^   *TLR9*        Toll like receptor 9                                     1.55 × 10^−4^   \<0.001     958   0.854
  ENSP00000294728 ^b^   *VCAM1*       Vascular cell adhesion molecule 1                        2.23 × 10^−4^   \<0.001     968   0.882
  ENSP00000292174 ^c^   *CXCR5*       C-X-C motif chemokine receptor 5                         1.14 × 10^−4^   0.001       976   0.820
  ENSP00000343204 ^a^   *JAK1*        Janus kinase 1                                           1.21 × 10^−4^   0.001       999   0.818
  ENSP00000162749 ^b^   *TNFRSF1A*    TNF Receptor superfamily member 1A                       2.30 × 10^−4^   0.001       999   0.826
  ENSP00000304414 ^c^   *CXCR6*       C-X-C motif chemokine receptor 6                         9.27 × 10^−5^   0.002       964   0.803
  ENSP00000296795 ^a^   *TLR3*        Toll like receptor 3                                     1.58 × 10^−4^   0.002       966   0.858
  ENSP00000231454 ^c^   *IL5*         Interleukin 5                                            1.13 × 10^−4^   0.004       991   0.803
  ENSP00000222823 ^a^   *NOD1*        Nucleotide binding oligomerization domain containing 1   7.72 × 10^−5^   0.004       991   0.866
  ENSP00000231449 ^b^   *IL4*         Interleukin 4                                            2.55 × 10^−4^   0.005       999   0.852
  ENSP00000356438 ^a^   *PTGS2*       Prostaglandin-endoperoxide synthase 2                    1.92 × 10^−4^   0.009       972   0.864
  ENSP00000219244 ^b^   *CCL17*       C-C motif chemokine ligand 17                            1.20 × 10^−4^   0.01        984   0.808
  ENSP00000351273 ^b^   *CASP8*       Caspase 8                                                9.66 × 10^−5^   0.027       999   0.821
  ENSP00000353483 ^c^   *MAPK8*       Mitogen-activated protein kinase 8                       1.03 × 10^−4^   0.034       925   0.847
  ENSP00000228280 ^c^   *KITLG*       KIT ligand                                               9.60 × 10^−5^   0.039       958   0.810
  ENSP00000238682 ^c^   *TGFB3*       Transforming growth factor β 3                           5.37 × 10^−5^   0.049       961   0.850

^a^: Genes with experiment evidence; ^b^: Genes without experiment evidence but have significant relationship with uveitis; ^c^: Genes without any evidence.
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###### 

Comparison of the RWR-based method and GBA-based method.

  Index of Part   RWR-Based Method   GBA-Based Method                               
  --------------- ------------------ ------------------ ------- --- ------- ------- -------
  1               0.172              0.089              0.118   1   0.207   0.061   0.094
  2               0.172              0.088              0.116   1   0.207   0.059   0.092
  3               0.379              0.177              0.242   3   0.345   0.039   0.069
  4               0.310              0.141              0.194   1   0.172   0.052   0.079
  5               0.400              0.211              0.276   3   0.500   0.061   0.109
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###### 

The pseudo-code of the RWR-based method.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RWR-Based Method
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Input:** Ensembl IDs of uveitis-related genes, a PPI network\
  **Output:** A number of putative uveitis-related genes

  Execute the RWR algorithm on the PPI network using the Ensembl IDs of uveitis-related genes as seed nodes, yielding a probability for each gene in the network; genes with probabilities higher than 10^−5^ were selected and called RWR genes;Execute a permutation test, producing the *p*-value for each RWR gene; select RWR genes with *p*-values less than 0.05; the remaining genes were called candidate genes;For each candidate gene, calculate its MIS (cf. Equation (3)) and MFS (cf. Equation (5)); select candidate genes with MISs no less than 900 and MFSs larger than 0.8;Output the remaining candidate genes as the putative uveitis-related genes.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
